Systemic Immunomodulation of Autoimmune Disease Using MHC-Derived Recombinant TCR Ligands

E-ISSN： 1875-5933|4|2|185-193

ISSN： 1568-010X

Source： Current Drug Targets. Inflammation & Allergy, Vol.4, Iss.2, 2005-04, pp. : 185-193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MHC ligands as potential therapeutics in the treatment of autoimmune and allergic diseases

By Guichard G.

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 1, 1997-01 ,pp. : 29-42

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Blockade of TCR Signal Transduction and Co-Stimulation in Autoimmune Disease

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 2, 2005-04 ,pp. : 205-216

Bentham Science Publishers

Access to resources Recommend Favorite

Endothelial Expression of MHC Class II Molecules in Autoimmune Disease

Current Pharmaceutical Design, Vol. 10, Iss. 2, 2004-01 ,pp. : 129-143

Bentham Science Publishers

Access to resources Recommend Favorite

Hydroxychloroquine/rifampicin interaction: Toxicoderma and worsening of systemic autoimmune disease: case report

Reactions Weekly, Vol. 1, Iss. 1411, 2012-01 ,pp. : 24-25

Adis International

Access to resources Recommend Favorite

The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimer's Disease

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 6, 2006-03 ,pp. : 597-608

Bentham Science Publishers

Access to resources Recommend Favorite